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Background and Aims: People who inject drugs (PWID) are at high risk of Hepatitis C virus 
(HCV) infection; however ~50% are undiagnosed in England and linkage-to-care is poor.  This 
study investigated the cost-effectiveness of an intervention (HepCATT) to improve case-
finding and referral to HCV treatment compared with standard-of-care pathways in drug 
treatment centres (DTCs) in England. 
Design: HCV transmission and disease progression model with cost-effectiveness analysis 
using a health-care perspective. Primary outcome and cost data from the HepCATT study 
parameterised the intervention, suggesting HepCATT increased HCV testing in DTCs 2.5-fold 
and engagement onto the HCV treatment pathway 10-fold. Model was used to estimate the 
decrease in HCV infections and HCV-related deaths from 2016, with costs and health 
benefits (quality-adjusted life-years or QALYs) tracked over 50 years. Univariable and 
probabilistic sensitivity analyses (PSA) were undertaken. 
Setting: England specific epidemic with 40% prevalence of chronic HCV among PWID. 
Participants: PWID attending DTCs. 
Intervention: Nurse facilitator in DTCs to improve the HCV care pathway from HCV case-
finding to referral and linkage to specialist care. Comparator was the standard-of-care HCV 
care pathway. 
Measurements: Incremental cost-effectiveness ratio (ICER) in terms of cost per QALY gained 
through improved case-finding. 
Findings: Over 50-years per 1000 PWID, the HepCATT intervention could prevent 75 (95% 
central interval 37-129) deaths and 1,330 (827-2,040) or 51% (30-67%) of all new 
infections. The mean ICER was £7,986 per QALY gained, with all PSA simulations being cost-
effective at a £20,000 per QALY willingness-to-pay threshold. Univariable sensitivity analyses 
suggest the intervention would become cost-saving if the cost of HCV treatment reduces to 
£3,900. If scaled up to all PWID in England, the intervention would cost £8.8 million and 
decrease incidence by 56% (33-70%) by 2030. 
Conclusions: Increasing Hepatitis C virus (HCV) infection case-finding and treatment referral 
in drug treatment centres could be a highly cost-effective strategy for decreasing HCV 
incidence among people who inject drugs. 
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Globally, infection with hepatitis C Virus (HCV) infection causes considerable morbidity(1).  Injecting 
drug use is the critical exposure in most developed countries(2). In the UK, people who inject drugs 
(PWID) account for 90% of new reported cases(3). HCV can now be easily cured with highly effective 
direct acting antiviral treatments (DAAs)(4), motivating the World Health Organisation (WHO) to set 
targets for eliminating HCV as a public health threat by 2030(5, 6).  The UK has adopted these 
targets(6) and has recently agreed an elimination tender with pharmaceutical companies to enable 
this(7).  However, low diagnosis and linkage-to-care rates for PWID remain a key barrier to achieving 
these elimination targets in the UK and globally(3, 8).  
UK guidance recommends undertaking case-finding in specialist drug clinics(9, 10) where a high yield 
of infection can be achieved(11). However, over 2005-2014, only 10% of cases identified in drug 
treatment centres were treated within a year, highlighting the need to improve the linkage-to-
treatment in these settings. There are few studies investigating the cost-effectiveness of such 
interventions(9, 12, 13), most from the pre-DAA era. The Hepatitis C Awareness Through to 
Treatment study (HepCATT) showed that a nurse facilitator within drug treatment centres in three 
English settings could improve the HCV care pathway from HCV case-finding, referral and linkage to 
specialist care(14). In this paper, we assess the cost-effectiveness of the HepCATT intervention 
compared to standard-of-care levels of testing and treatment amongst PWID in England. Insights 
from this analysis will be important for advocating for the further expansion of community-based 
case-finding and linkage-to-treatment interventions in the UK, some of which now include 
community-based treatment(15-18).    
 
Methods 
The cost-effectiveness analysis compared the costs and impact of increased testing and engagement 
achieved among PWID through the HepCATT study in drug treatment centres to a counterfactual 
where the current standard-of-care levels of testing and engagement continues (status quo). The 
analysis was undertaken from a UK National Health Service (NHS) and Personal Social Services 
perspective, following National Institute for Health and Care Excellence (NICE) guidelines over a 50-
year time horizon(19). Personal Social Services include services not normally covered by the 
NHS(20), including drug treatment services and the HepCATT intervention being evaluated in this 
analysis. The analysis incorporated health benefits of preventing long-term disease sequelae among 
individuals treated for HCV infection and onward transmission prevention benefits for other PWID. 
Costs (2018 GB pounds) and health utilities (quality-adjusted life years or QALYs) were attached to 
each disease stage, each discounted at 3.5% per year. The analysis follows broad best practise in 
clearly describing all details of the modelling, giving details of the derivation of all model parameters, 
calibrating and validating the model against available data, and incorporating parameter 
uncertainty(21, 22). The analysis did not follow a pre-registered analysis plan but used similar 
methods to our previous studies(9, 23). 
 
Mathematical model 
The cost-effectiveness analysis was conducted using an open dynamic model of HCV transmission 
and disease progression among current and former PWID, including diagnosis and treatment (see 
Figure 1; model equations in supporting information). The modelled population was stratified by 
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whether individuals were receiving opioid substitution therapy (OST) or not, which was used as a 
proxy for drug treatment centre attendance, where HepCATT took place.   
People who start injecting drugs enter the model as susceptible individuals not on drug treatment. 
Individuals become HCV-infected at a rate dependent on the prevalence of infection, with those on 
OST/drug treatment having reduced risk of infection(24).  Newly infected individuals either 
spontaneously clear their infection (antibody positive and RNA-negative) or become chronically 
infected (antibody and RNA-positive)(Figure 1b), which is life-long unless treated.  Upon primary 
infection, liver disease progression occurs as in Figure 1c, with HCV-related death occurring from any 
stage after compensated cirrhosis. At any time, current injectors can initiate OST for an average 
duration and can die from drug related mortality or permanently cease injecting.  Cessation from 
injecting is assumed to be independent of OST based on long-term cohort data of PWID from the UK 
that showed no clear association(25).  Following cessation, individuals can no longer become HCV-
infected, but can die due to natural causes and HCV (if infected) and can receive HCV treatment. 
Chronically infected individuals can be diagnosed at a per capita rate depending on rates of testing 
and are either lost to follow up (LTFU) or engaged in the treatment pathway.  Rates of testing 
depend on whether an individual is attending drug treatment or not. Engagement is defined as 
attending the hepatology clinic, whereupon they are treated at a per capita rate and either achieve 
effective cure (sustained virologic response, SVR) or fail treatment and continue to be chronically 
infected. Re-treatment of those who fail treatment occurs at the same rate as for initial treatment. 
Disease progression continues at a decreased rate in cured individuals who have compensated or 
decompensated cirrhosis and ceases in those with milder disease(26, 27). Cured individuals can be 
re-infected at the same rate as for primary infection, where upon disease progression continues 
from their current disease stage. Individuals who are LTFU are only re-engaged with the treatment 
pathway once they progress to compensated cirrhosis or more severe disease, or become in contact 
with HepCATT.  
 
[insert figure 1] 
 
Parameterisation and calibration of the standard-of-care model 
The model was parameterised and calibrated to represent a generalised UK scenario using data from 
the annual unlinked anonymous monitoring (UAM) survey for PWID(28), baseline data collected for 
HepCATT(14), and HCV sentinel surveillance data collected from multiple testing settings(11). See 
Table 1. The UAM survey gave us the mean HCV antibody prevalence (52%) among PWID in England 
and Wales for 2015(28), or approximately 40% chronic prevalence(29). Estimates suggest 63% of 
PWID are currently on OST(28), with an average duration on OST of 8 months(30). We assume stable 
OST coverage and HCV prevalence among PWID in recent years(28, 31).  Based on a recent Cochrane 
systematic review, we assume being on OST reduces the risk of HCV transmission by 59%(24). The 
percentage of chronically infected PWID who were diagnosed before the intervention was assumed 
to be 52%(28), with the standard-of-care testing rate at drug treatment centres (14% in last year) 
being estimated using baseline HepCATT data(14). The testing rate outside drug treatment centres 
was estimated through model calibration.  The standard-of-care rate of engagement with the 
treatment pathway following diagnosis at drug treatment centres was estimated using baseline 
HepCATT data and a study on the cascade of care for different testing settings in England(11).  The 
treatment rate for engaged individuals was estimated using baseline HepCATT data and was 
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assumed to be the same irrespective of where testing occurred. Although higher treatment rates 
may have been achieved recently, data is uncertain and so are only considered in the sensitivity 
analysis. We assumed the pre-2016 (pre-DAA) SVR was 49.5%(11) and the DAA SVR was 93%(32).  
 
[insert table 1] 
 
For the model calibration, 1000 parameter sets were sampled from the parameter distributions in 
Table 1.  For each sampled parameter set, the transmission rate, OST recruitment rate and HCV 
testing rate for non-drug treatment settings were varied to fit the model (using MATLAB solver 
function lsqnonlin) to sampled values for the HCV chronic prevalence amongst current PWID in 
2015, OST coverage and overall proportion diagnosed. This assumed the system was in steady state 
before 2016. Only parameter sets where the proportion diagnosed was within its uncertainty range 
were accepted as model fits; the model was always able to fit to the HCV prevalence and OST 
coverage. The resulting 720 model fits were used to simulate the standard-of-care and intervention 
scenarios. The calibration process is described further in the supporting information. 
 
Standard-of-care comparator arm 
The standard-of-care scenario assumes that testing, engagement and treatment are maintained at 
pre-HepCATT levels (Table 1) for individuals tested in all settings, with DAA therapy being 
undertaken in hospital clinics. 
 
Intervention arm 
Based on results of the HepCATT study, we modelled an intervention scenario where the odds of 
testing in drug treatment centres increased 2.5-fold and the odds of engagement onto the 
treatment pathway increased 10-fold from 2016(14). We also assumed that individuals attending 
drug treatment centres that were previously LTFU could be re-engaged onto the treatment pathway 
at the same rate as those newly diagnosed due to the nurse liaison intervention.  Parameter ranges 
for the standard-of-care and intervention scenarios are given in Table 2. 
 
[Insert Table 2] 
 
Impact analysis 
The number of infections and disease-related deaths averted between 2016 and 2030 or 2066 were 
estimated by comparing the projections of the standard-of-care and HepCATT model scenarios.  The 
relative difference in the incidence and prevalence of HCV by 2030, and proportion of chronically 
infected PWID diagnosed was also estimated. 
 
Costs and Utility Values 
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Costs and utilities from the literature are given in Table S7. Health utilities (quality adjusted life years 
[QALYs]) and HCV disease progression rates came from previous studies(26, 27, 33-35), with health 
utilities for HCV disease progression states(33) being multiplied by the baseline health utilities for 
PWID(36) or ex-PWID.  Healthcare costs relating to HCV disease were taken from previous economic 
analyses(33, 35).  Costs relating to the treatment pathway in hospitals using DAAs were based on the 
NHS treatment protocol (personal communication Graham Foster;  see supplementary materials) 
and NHS reference costs(37).  Costs were inflated to 2018 British Pounds using the Health and 
Community Hospital Service pay and prices index(38).  
  
Costs for the HepCATT intervention (improving testing and engagement) were calculated from time 
allocation and resource use (number of antibody and RNA tests) data collected (top down approach) 
through interviews with nurses and keyworkers involved in the intervention from two cities.  Staff 
time was allocated to either administration and management costs, diagnosis costs or engagement 
costs. Nurse salaries came from study records.  Keyworker salaries and overhead costs (rent, 
utilities) were obtained from the drug treatment provider (Addaction) undertaking the intervention. 
Management, overheads and training costs were assigned to give a fixed yearly cost, with a greater 
cost in the first year due to additional staff training.  Peer-workers were volunteers, so opportunity 
costs were applied equivalent to the minimum keyworker salary.  Dried blood spot testing costs 
were obtained from the laboratory, which was a cost incurred by the intervention. Costs for testing 
per patient were calculated by summing staff and resource costs for the diagnosis stage and dividing 
by the number tested.  The costs of engagement per patient were calculated by summing 
engagement costs (for all referred individuals regardless of attendance) and dividing by the number 
of patients engaged in the treatment pathway. For HepCATT, this included costs for getting 
individuals to hospital appointments, including keyworker and peer time, and for both arms included 
the costs of preliminary blood tests and fibroscan at the hospital. Costs for testing in other settings 
were taken from a published UK cost analysis of reflex testing(11), where samples are automatically 
tested for HCV RNA if they test antibody-positive.  All testing was assumed to be reflex testing.  
Published costs for OST specialist prescribing were used, which incorporated staff time, prescribing 
costs and drug costs(38). 
 
Cost-effectiveness analysis 
Costs (2018 British Pounds, £1=$1.41) and health utilities were attached to each model state. The 
analysis used a 50-year time horizon to capture long-term effects of HCV infection and population 
prevention benefits of HCV treatment.  The incremental cost-effectiveness ratio (ICER) was 
calculated as the difference in mean costs divided by the difference in mean QALYs between the 
intervention and the standard-of-care scenario. Cost-effectiveness was determined using the UK 
willingness-to-pay threshold of £20,000 per QALY gained(19).   
 
Sensitivity analysis 
A probabilistic sensitivity analysis (PSA) was performed for both modelled scenarios, and cost-
effectiveness acceptability curves were plotted.  The impact of parameter uncertainty on the 
incremental costs and QALYs was assessed using an ANCOVA analysis across the model fits(39).  
Matched univariable sensitivity analyses examined the effect of:  
7 
 
a) varying the time horizon (100 or 15 years compared to 50 years) or discount rate (0% and 6% 
compared to 3.5%) across a wide range as recommended by NICE;  
b) reducing the HCV drug cost by 80% (£7,796 per 12-week treatment course) to typify what the 
current cost of treatment in England could be, although the actual price is unknown; 
c) increasing the treatment rate from engagement in all settings to 80% (from 16%-45%) within a 
year to determine how increased treatment uptake may affect the cost-effectiveness of the 
intervention; and   
d) varying chronic HCV prevalence to 20% or 60% (compared to 40%) to capture the range of HCV 
prevalences observed in different UK or international settings(40, 41). 
The impact of decreasing drug costs was also investigated in a threshold analysis, whereby the mean 
ICER was calculated for different drug costs to determine at what price the intervention becomes 
cost saving. Finally, an expected value of perfect information (EVPI) analysis was carried out(39) at 




The intervention is estimated to increase the number of PWID tested annually 2-fold (95%CrI 1.5-
2.5) and the number treated 2.9-fold (95%CrI 2.3-6.1) (Figure S1). This increase in treatment is 
estimated to avert 75 deaths (95%CrI 37-129), 1330 infections (95%CrI 827-2040) and gain 1,607 
QALYs over 50 years per 1000 PWID, or in England assuming 139,830 PWID(42) then it would avert 
10,487 deaths (95%CrI 5,174-18,038), 185,974 infections (95%CrI 115,639-285,253) and gain 
224,707 QALYs.  This equates to 64% (95%CrI 50-72%) of all HCV-related deaths and 51% (95%CrI 30-
67%) of all infections being averted over this period and a 56% (95%CrI 38-70%) decrease in chronic 
HCV prevalence and incidence by 2030 (Figure 2). The number of disease related deaths decreased 
by 29% (95%CrI 20-39%) over the same period.  
 
[Insert Figure 2] 
 
Costs of the intervention 
There was one half-time nurse liaison associated with each setting during the intervention. 
Involvement of keyworker staff varied across settings with one keyworker supervising the peer 
workers for between 1 or 2 days a week. The remaining keyworkers at the two settings each had 1-
1.5 days of training for HepCATT. In one setting, there were 9 keyworkers who each spent 0.03 full-
time equivalent (FTE) or 0.28 FTE altogether on HepCATT and 6 peers who spent 0.14 FTE altogether. 
In the second setting, there were 48 keyworkers and 15 peers totalling 0.38 FTE and 0.5 FTE, 
respectively.  Table 3 shows the allocation of HepCATT costs to different stages of the diagnosis and 
engagement pathway; Table S8 gives a breakdown of standard-of-care costs.  Once set-up, the 
ongoing yearly fixed costs of HepCATT are £12,385 (includes one round of peer worker training), 
while the average cost to engage a previously undiagnosed or diagnosed patient on to treatment is 
£682 and £600, respectively. All stages of the pathway to engagement are more costly than the 
standard-of-care reflecting the increased staff time associated with HepCATT. 
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[Insert Table 3] 
The breakdown of costs applied over the 50-year time horizon per 1000 PWID are shown in Table 4.  
The total incremental cost of the intervention was £12.8 million for the full list drug price. This was 
made up of extra expenditure (£15.8 million), mainly in testing and engagement (HepCATT, £1.0 
million) and HCV treatment (PWID and ex-injectors, £14.8 million), and cost savings (£3.0 million) in 
HCV-related healthcare costs. For the England population of PWID, the incremental costs increase to 
£1,789.8 million for the full price of DAAs, with the intervention costing £144.8 million over 50-years 
or £8.8 million to 2030 (discounted). The annual intervention cost is more than the standard-of-care 
scenario until 2048 (Figure S2).   
[Insert Table 4] 
Base case cost-effectiveness analysis 
Table 5 shows the results of the cost-effectiveness analysis over 50-years. For the full list DAA price, 
the Intervention costs £12.8 million more than the standard-of-care scenario, but accrues 1,607 
extra QALYs, giving a mean ICER of £7,986 per QALY gained. The cost-effectiveness plane (Figure S3) 
shows that all simulations are below the £20,000 per QALY willingness-to-pay threshold.   
[Insert Table 5] 
Sensitivity analysis 
The results were robust to numerous univariable sensitivity analyses, with the ICER remaining below 
the £20,000 per QALY willingness-to-pay threshold (Figure 3).  Decreasing the discount rate, 
lengthening the time horizon or reducing the HCV treatment drug cost by 80% all decreases the 
mean ICER making the intervention more cost-effective. Indeed, an 80% decrease in drug cost 
causes the total incremental cost of the intervention to reduce to £1,145,245 per 1000 PWID or 
£160,139,908 for an England population of 139,830 PWID. Similarly, increasing the proportion of 
engaged individuals that start treatment to 80% (from 16%-45%) decreases the ICER to £4,321 per 
QALY gained, and achieves a 77% (95%CrI 57-87%) reduction in incidence by 2030. Assuming a lower 
chronic HCV prevalence (20%) does not affect the ICER much (£5,692 per QALY), while assuming 
higher chronic prevalence (60%) increases the ICER to £17,797 per QALY.   
[Insert Figure 3] 
The threshold analysis (figure S4) shows the intervention becomes cost-saving (costs less than the 
standard-of-care comparator and saves more QALYs) for a 90% reduction in drug price (£3,898 per 
12-week regimen). The ANCOVA (figure S5) shows that uncertainty in the annual HCV-related 
healthcare costs accounted for 80% of the variation in incremental costs, while uncertainty in the 
treatment rate and utility values for mild disease (F0-F1) resulted in 59% of the variability in 
incremental QALYs.  The EVPI was zero as all simulations are cost-effective at the £20,000 per QALY 
willingness-to-pay threshold.  
 
Discussion 
Introducing a nurse led intervention (with peer support) to improve the HCV testing and 
engagement to care of PWID attending drug treatment centres is cost-effective (£7,986  per QALY 
saved) at current list prices for DAA HCV treatment (£39,000 per treatment), and becomes cost-
saving if drug costs decrease to £3,900 per treatment.  Moreover, if the intervention were scaled up 
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to all drug treatment centres in England, it could avert 51% of infections and 64% of HCV-related 
deaths over a 50-year period and reduce incidence by 56% by 2030.  Optimising the intervention 
further, with 80% of people being treated within a year of engagement results in the intervention 
becoming more cost-effective (£4,321 per QALY for full list price of DAAs) and could reduce 
incidence by 77% by 2030. Because most on-going HCV transmission in the UK is among PWID(2), 
these impact projections suggest that this intervention could be an important component of the 
NHS-England initiative to reach the WHO elimination targets of decreasing HCV incidence by 90% by 
2030 or earlier. National estimates for scaling up the intervention suggest it would cost £144.8 
million over the next 50 years or £8.8 million by 2030 (discounted). 
 
Strengths and Limitations 
The main strength of our study is that we evaluate a real-life intervention using empirical data on 
the outcomes of the intervention and costs. We also use a dynamic HCV transmission model to 
capture the prevention benefits of the intervention, while incorporating uncertainty in all model 
parameters. Nonetheless, potential limitations still exist.   
Firstly, the estimates for fixed intervention costs, which include management (staff time and building 
costs) and training costs, are based on two of the three study settings.  This was deemed appropriate 
because these two settings were of differing sizes in terms of PWID population but still had similar 
set up costs.   
Secondly, a generic English setting was modelled to make our results relevant to the whole of 
England. However, OST coverage and HCV prevalence vary across England and the intervention’s 
cost-effectiveness may depend on these inputs. Indeed, the cost-effectiveness of the intervention 
diminishes at higher chronic HCV prevalences (60%) due to greater reinfection(43), although it is still 
cost-effective. In contrast, variation in the coverage of OST (proportion of PWID currently on OST) is 
unlikely to affect the cost-effectiveness of the intervention, with the uncertainty included in our 
analysis (60-65%) not effecting our results.  However, the impact of the intervention will be lessened 
at lower OST coverage levels because the reach of the case-finding strategy will be reduced. This 
could also occur if many PWID inject stimulants which OST is not an effective intervention for.  
Lastly, the analysis used data on the overall proportion of PWID diagnosed with HCV to obtain a 
testing rate in settings other than drug treatment centres.  Although a wide range of testing rates 
were used (0.01-0.45 per year) in the standard-of-care comparator, it is likely that testing rates have 
increased across all services because of the on-going expansion of HCV treatment.  It is unclear how 
this will affect the cost-effectiveness of this intervention, although solely improving the proportion 
of engaged individuals that start treatment improves the cost-effectiveness of the intervention in 
our sensitivity analyses.   
 
Comparison with other studies 
This is the first UK and European study to evaluate the cost-effectiveness of a real-life case-finding 
intervention among PWID since the emergence of DAA therapies. Our findings are consistent with 
other studies which find case-finding among PWID to be cost-effective when sufficient diagnosed 
individuals are treated(9, 12, 13, 44), with some of these interventions also providing onsite HCV 
treatment in drug treatment centres to improve linkage to treatment(45). Only two of these studies 
considered the use of new DAA therapies(12, 44), finding that HCV screening through drug 
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treatment centres with active linkage to treatment was cost-effective in New York city (<$35,000 per 
QALY gained). Two other European studies before the emergence of DAA therapies considered the 
cost-effectiveness of case-finding interventions for PWID, with both including scenarios that 
assumed the use of a ‘DAA-like’ treatment with higher drug cost and SVR.  One UK study found 
introducing dried blood spot testing in drug treatment centres was cost-effective at less than 
£15,000 per QALY when assuming the use of interferon-based treatments or first generation 
DAAs(9). Another study from the Netherlands evaluated testing in drug treatment centres 
(comparator was no testing), finding it to be similarly cost-effective (Euro 9,056 per QALY) to our 
intervention (at full list price). However, they assumed 77% of diagnosed cases were referred and 
37% of these cases were treated (13), considerably higher than we assumed for our analysis. 
 
Conclusions and implications 
Drug treatment centres are a high yield setting for identifying individuals that require HCV 
treatment(11). Our study provides evidence that introducing HCV nurse facilitators in drug 
treatment centres is highly cost-effective, potentially cost-saving if HCV drug prices fall sufficiently, 
and if scaled-up could reduce HCV incidence by 56% by 2030 for an estimated direct intervention 
cost of £8.8 million if scaled up nationally. This could contribute considerably to national targets for 
achieving HCV elimination as a public health problem. Better engagement and so greater impact 
could be achieved if this intervention also provides HCV treatment onsite as has been piloted in 
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Table 1 Demographic and epidemic model parameters.  
Parameter Description Point Estimate Sampled Distribution Rationale Source 
Rate of cessation of injecting per year – set 
as 1/ injecting duration 
1/11.5 Injecting duration 
Uniform (8,15) 
Mean injecting duration 11.5 years, 
assumption for sampled range 
(45) 
Drug related death rate per year 0.0073 Poisson Distribution 
mean=0.73 /100 
Data suggests 45-84 deaths per 10,000 
person years among opiate users identified 
from drug treatment and criminal justice 
records in England (2005-2009) 
(46) 
Death rate amongst individuals that have 
ceased injecting (per year) 
0.026 Life expectancy 
Uniform (70,80) 
Age at initiation of injecting 
Uniform (20,30) 
1/(life expectancy-age at initiation of 
injecting-injecting duration) 
 
World bank life 
expectancy data, UAM 
data 
Initiation rate of new injectors 




 Fitted assuming a constant population size of 
1000 or UK population size and sampled 
death and cessation rates for current 
injectors 
 
Proportion of treated individuals that 
achieve SVR pre 2016 
0.49 Uniform (0.483,0.507) UK SVR data from sentinel surveillance (11) 
Proportion of treated individuals that 
achieve SVR post 2016 
0.93 Uniform (0.88,0.98) Results from SIMPLIFY phase 4 trial using 
sofosbuvir and velpatisvir in people with 
recent injection drug use 
(32) 
Rate at which people start attending drug 




 Fitted to give a coverage of OST (proportion 
of PWID currently on OST) that is uniformly 
sampled between 60-65% from Unlinked 
Anonymous Monitoring Survey 
(40) 
Rate at which people stop attending drug 




Years on OST  
Uniform (0.33,1) 
Duration on OST was 8 months (4-12 
months) in cohort of PWID in UK 
(30) 
Reduced risk of HCV transmission due to 
being on OST 
0.41 Lognormal (0.22,0.74) Cochrane Review (24) 
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Parameter Description Point Estimate Sampled Distribution Rationale Source 
HCV Ab prevalence 52% Normal (CI 51-55%) From literature (28) 
Baseline transmission rate Estimated 
through model 
calibration 
 Fitted using sampled Ab prevalence * (1-
proportion of infections that spontaneously 
clear).  
 
Proportion of infections that 
spontaneously clear  
0.26 Uniform (0.22,0.29) From literature (29) 
Rate at which individuals complete 
treatment = 1/treatment duration 
(per year) 
52/12 Constant 12 weeks for DAA treatment NICE guidelines 
 




Table 2: Parameters related to HCV treatment pathway for the standard-of-care and intervention scenario 
Parameter Standard-of-care Source Intervention Source 
Testing Rate per year 
Drug Treatment Centres 0.140 (0.075-0.259) HepCATT baseline data(47) 0.332(0.167-0.586) HepCATT intervention dat; see 
supplementary information for more 
details (47) 
Other Settings and Ex-injectors Varied to give 
required proportion 




 Same as for standard-of-
care 
Assume intervention has no impact on 
other settings 
Engagement Rate per year 
From Drug Treatment Centres 
within 1 year of diagnosis 
0.092 (0.035-0.242) HepCATT baseline data(47) 0.741 (0.206-1.634) HepCATT intervention data(47) 
From Other Diagnosis settings 
within 1 year of diagnosis 
0.092 (0.035-0.242) HepCATT baseline data(47) Same as for standard-of-
care 
 
From Drug Treatment Centres 
after 1 year since diagnosis 
0 unless disease stage 
is F4 or above 
Assumption that after 1 year patients 
are lost to follow up until 
symptomatic  
0.741 (0.206-1.634) HepCATT intervention data(47) 
From Other Settings after 1 year 
since diagnosis 
0 unless disease stage 
is F4 or above 
Assumption that after 1 year patients 
are lost to follow up until 
symptomatic 
Same as standard-of-care Assume intervention has no impact on 
other settings 
Treatment rate per year 
All Settings 0.330 (0.170-0.590) HepCATT baseline data(47) Same as for standard-of-
care 
Assume intervention has no impact on 
treatment at hospital clinic 
Proportion of treated individuals 
that achieve SVR post 2016 
0.93 Uniform (0.88,0.98) Results from SIMPLIFY 
phase 4 trial using 
sofosbuvir and velpatisvir 
in people with recent 





Table 3: Costs related to testing and linkage to treatment  
Step Standard-of-care Cost  Intervention Cost Source 
HepCATT startup cost for first year including 
management staff time during project initiation, 
nurse staff training and peer worker training 
0 [£25,403-£34,712] HepCATT costing analysis (see supplementary 
information) 
Second and Subsequent Years fixed costs for 
HepCATT includes management, staff project 
oversight and one round of peer worker training 
0 [£10,951-£13,818] 
Costs per Test (includes 
staff time and test 
costs) 
Ab negative  £53 +/- 10% [£106 - £161] (11) and HepCATT costing analysis (see supplementary 
information) Ab positive  £119 +/- 10% [£150 - £212] 
Previous known SVR 
(Ab+) 
£119 +/- 10% [£146 - £207] 
Costs per Engagement 
(includes staff referral 
costs and preliminary 
blood tests and 
fibroscan at the 
hospital) 
From Diagnosed  £409 +/- 10%  [£124-£212] (referral cost) 
+[£332±10%] (at hospital) 
Standard-of-care referral costs from (11), hospital costs 
from expert opinion (correspondence Graham Foster) 
Intervention referral costs from HepCATT costing 
analysis (see supplementary information) 
 
From Lost to Follow Up £409 +/- 10% (later 




(referral cost) +[£332±10%] 
(at hospital) 
Cost per Treatment Treatment Monitoring £394 +/- 10% 
 
Expert opinion (correspondence Graham Foster and 
supplementary information for details) 
Weekly Drug Cost £3,249 +/-10% 
 
Assume full current list price (48) 





Table 4: Breakdown of discounted costs over 50-year time horizon  
 Standard-of-care mean Intervention mean Difference 
HCV related 
Healthcare 
£9,306,667 £6,261,626 -£3,045,041 
HCV treatment ex-
PWID 
£3,318,512 £5,001,366 £1,682,854 
HCV treatment 
PWID 
£1,894,516 £14,998,725 £13,104,208 
Testing and 
Engagement * 
£424,988 £1,460,213 £1,035,225 
OST £48,078,808 £48,137,935 £59,127 
Total £63,023,491 £75,859,865 £12,836,374 
*Includes cost of testing and engagement in drug treatment centres and other settings and testing 
and engagement of ex-injectors. Initial population size of PWID is 1000, injector population is 















(£ per QALY) 
Standard-of-care £63,023,491  36,865   







Figure 1: Schematic of the model structure for (a) population stratification by PWID and harm 










Figure 2: Model projections of the (a) chronic prevalence and (b) incidence of HCV with and without 
the HepCATT intervention, with data on the prevalence of HCV in 2016 (which the model was fit too) 
and incidence of HCV for 2015 and 2016 (which the model was not fit too) being shown for 
comparison. Points are the mean of the data estimates with the whiskers showing the 95% 
confidence intervals. The black solid or dashed lines show the median of the model projections with 
the shaded areas denoting the 95% central range of the model projections. 
(a) Chronic prevalence of HCV 
 








Figure 3: Tornado plot showing the effect of changing different model assumptions on the mean 










A. Infection and treatment sub-model 
This sub-model stands alone and can be used to investigate the impact of treatment on the 
prevalence of HCV a population of people who inject drugs. 
Notes: The letter 𝑆𝑖
𝑘,𝑚 denotes a susceptible individual.  The superscript k is either 0 or 1 denotes 
injector and ex-injector respectively.  The superscript m is from 1,2,..9 denoting the disease 
progression state (more on this sub-model below).  The subscript i is either 0 or 1 and denotes off or 
on OST respectively.   




Exposed individuals but not infected (Ab+, RNA-) 𝐸𝑖
𝑘,𝑚 
Chronically infected individuals (Ab+, RNA+) 𝐶𝑖
𝑘,𝑚 
Diagnosed infected individuals 𝐷𝑖
𝑘,𝑚 
Infected individuals engaged in treatment pathway 𝑁𝑖
𝑘,𝑚 
Lost to follow up infected individuals 𝐿𝑖
𝑘,𝑚 
Infected individuals undergoing Treatment 𝑇𝑖
𝑘,𝑚 
Individuals who have attained SVR and are no longer infected 𝑉𝑖
𝑘,𝑚 
Infected individuals who have Failed treatment 𝐹𝑖
𝑘,𝑚 
 
Table S2: Definition of the model parameters 
Parameters Symbols Units 
Infection rate 𝜆 per year 
Relative risk of transmission/acquisition of HCV 
when on OST 
Β None 
Proportion of infections that spontaneously clear 𝛿 None 
Testing rate  𝜏𝑖 Per year 
Engagement rate from diagnosed 𝜌𝑑 Per year 
Engagement rate from lost to follow up 𝜌𝐿
𝑚 Per year 
Transition rate from diagnosed to lost to follow up 𝜖 Per year 
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Parameters Symbols Units 
Treatment rate from engaged 𝜔𝑚 Per year 
Length of time on treatment 𝜎 Years  
Proportion of treatments that attain SVR 𝛼 None 
Death rate in injectors 𝜇1 Per year 
Death rate in ex-injectors  𝜇5 Per year 
Inflow of new injectors  𝜃 People per year 
 
Notes: The testing rate depends on contact with drug treatment services (OST). We assume that 
those on OST (𝑖 = 1) have an increased rate of testing.  The engagement rate from Lost to follow up 
(𝜌𝐿) depends on the current disease progression state.  At baseline, we assume that 𝜌𝐿 = 0 for 𝑚 =
1,2,3 amd 𝜌𝐿 = 𝜌𝑑 for 𝑚 > 3.  The treatment rate from engaged also depends on the current 
disease progression state.  For 𝑚 < 7 the treatment rate is non-zero, otherwise it is zero. 
 

























Which gathers together all individuals in the population within the same OST status. 














Define Λ𝑖 as the multiplier of the force of infection which depends on OST status where 
Λ0 = 1,Λ1 = Β, 
  This allows the following system of equations for the infection part of the model 
 
?̇?𝑖





0,𝑚 =  𝛿Λ𝑖𝜙𝑆𝑖
0,𝑚 − (𝜇1 + 𝜈 + (1 − 𝛿)Λ𝑖𝜙)𝐸𝑖
0,𝑚 
?̇?𝑖
0,𝑚 = (1 − 𝛿)Λ𝑖𝜙𝑆𝑖
0,𝑚 + (1 − 𝛿)Λ𝑖𝜙𝐸𝑖
0,𝑚 + (1 − 𝛿)Λ𝑖𝜙𝑉𝑖





























0,𝑚 = (1 − 𝛼)𝜎−1𝑇𝑖




When ex-injectors are included in the model (𝑘 = 1), there are no new infections in ex-injectors, 
but they can be diagnosed and treated as for current injectors. 
 
B. Demographics sub-model 
Table S3: Definition of the model state variables 
Variable Symbols Example 
Susceptible injector, not on OST 𝑆0
0,𝑚 
Susceptible injector, on OST 𝑆1
0,𝑚 
Susceptible ex-injector (not on OST) 𝑆0
1,𝑚 
  
Table S4: Definition of the model parameters 
Parameter Symbol Units 
Transition rate from off OST to on OST 𝛽 Per year 
Transition rate from on OST to off OST 𝛾 Per year 
Injecting cessation rate 𝜈 Per year 
 
The terms for the differential equations for this part of the model are given by the following system 
(𝑂𝑆), where 𝑂𝑆𝑖
𝑘,𝑚 are the terms concerning movement between OST and injecting states for 
variable 𝑆𝑖
𝑘,𝑚 and are valid for all infection sub-model states (different variable letters) and disease 






















−𝛽 − 𝜈 𝛾 0
𝛽 −𝛾 − 𝜈 0
𝜈 𝜈 0
) 
C. Disease Progression sub-model 
The following sub-model variables and terms can be included to explore disease progression in the 
population. 
Table S5: Definition of the model state variables 

















Post Liver Transplant 𝐶𝑖
0,9 
 
Table S6: Definition of the model parameters 
Parameter Symbol 
Yearly progression rate from f0 to f1 𝜁1 
Yearly progression rate from f1 to f2 𝜁2 
Yearly progression rate from f2 to f3 𝜁3 
Yearly progression rate from f3 to compensated 
cirrhosis 
𝜁4 
Yearly progression rate from compensated 
cirrhosis to decompensated cirrhosis 
𝜁5 
Yearly progression rate from compensated 
cirrhosis or decompensated cirrhosis to 





Yearly progression rate from decompensated 
cirrhosis or HCC to liver transplant 
𝜁7 
Yearly progression rate from liver transplant to 
post liver transplant 
𝜁8 
Decompensated cirrhosis related death rate per 
year 
𝜁6 
Hepatocellular carcinoma related death rate 
per year 
𝑑7 
Liver transplant related death rate per year 𝑑8 
Post liver transplant related death rate per year 𝑑9 
Relative risk for progression rate from  
compensated to decompensated cirrhosis 
following SVR 
𝑒5 
Relative risk for progression rate from 
compensated cirrhosis to HCC following SVR 
𝑒6 
 
These terms in the equations are concerned with movement through the disease states.  Infection 
and treatment are described separately above.  𝐷𝑌𝑖
𝑘,𝑚 denotes the terms in the ordinary differential 
equation of disease category 𝑚 for susceptible individuals who have previously been treated and 
𝐷𝐶𝑖
𝑘,𝑚  for infected individuals.  These terms can be found in the equations for all values of 𝑖, 𝑗, 𝑘 and 


















































−𝜁1 0 0 0 0 0 0 0 0
𝜁1 −𝜁2 0 0 0 0 0 0 0
0 𝜁2 −𝜁3 0 0 0 0 0 0
0 0 𝜁3 −𝜁4 0 0 0 0 0
0 0 0 𝜁4 −𝜁5 − 𝜁6 0 0 0 0
0 0 0 0 𝜁5 −𝜁6 − 𝜁7 − 𝑑6 0 0 0
0 0 0 0 𝜁6 𝜁6 −𝜁7 − 𝑑7 0 0
0 0 0 0 0 𝜁7 𝜁7 −𝜁8 − 𝑑8 0





























































































0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 −𝑒5𝜁5 − 𝑒6𝜁6 0 0 0 0
0 0 0 0 𝑒5𝜁5 −𝜁6 − 𝜁7 − 𝑑6 0 0 0
0 0 0 0 𝑒6𝜁6 𝜁6 −𝜁7 − 𝑑7 0 0
0 0 0 0 0 𝜁7 𝜁7 −𝜁8 − 𝑑8 0














































As an example as to how this all works together, below are two differential equations for susceptible 
and chronically infected individuals who are current injectors (𝑘 = 0), on OST (𝑖 = 1) and in Metavir 










0,1 = −(𝜇1 + 𝜈 + 𝛾)𝐶1
0,1 +  𝛽𝐶0





Model Calibration procedure 
The sampled HCV prevalence and proportion of PWID diagnosed was used to fit the overall infection 
rate and HCV testing rate in other settings (using pre-DAA treatment efficacy).  Fitting was carried 
out using the least squares non-linear fitting function, lsqnonlin, in Matlab in a sub-model without 
disease progression that does not include ex-injectors.  Using the testing rate and infection rate 
found using this method the initial conditions of the full model with disease progression are 
obtained by running the system to steady state.   
 




2018 £ Distribution Source 





HCV Uninfected 0 - 
(33) 
 













































Health Utility Weights    
Uninfected    
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Ex / non-PWID 0.85 Uniform (0.8-0.9) 
assumpti
on 
PWID 0.73 Uniform (0.68-0.78) (36) 
Mild HCV (F0 and F1)    





SVR  0.82 
Beta 
(65.8678,14.4588) 
Moderate HCV (F2 and F3)   
Without Treatment 0.66 
Beta (168.2461, 
86.6723) 
SVR 0.72 Beta (58.0608,22.592) 
Compensated Cirrhosis    






Decompensated cirrhosis 0.45 Beta (123.75, 151.25) 
Hepatocellular Carcinoma 0.45 Beta (123.75, 151.25) 




PPI payment price index (38) 
 
Table S8: Disease Progression rates 
Parameter Distribution Source 
Yearly progression rate from F0 to F1 0.0529-0.2095  PWID specific 
instantaneous rates 
from (34) – sampled 
from normal 
distribution 
Yearly progression rate from F1 to F2 0.0216-0.1013  
Yearly progression rate from F2 to F3 0.0450-0.1145  
Yearly progression rate from F3 to compensated 
cirrhosis 
0.0513-0.1838 
Yearly progression rate from compensated cirrhosis to 
decompensated cirrhosis 






Yearly progression rate from compensated cirrhosis or 
decompensated cirrhosis to hepatocellular carcinoma  
0.0003-0.0684 
Yearly progression rate from decompensated cirrhosis 
or HCC to liver transplant 
0.0062-0.0962 
Yearly progression rate from liver transplant to post 
liver transplant 
1.0423-2.4412 
Decompensated cirrhosis related death rate per year 0.1063-0.1842 
Hepatocellular carcinoma related death rate per year 0.3904-0.7697 
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Parameter Distribution Source 
Liver transplant related death rate per year 0.0911-0.4348 
Post liver transplant related death rate per year 0.0280-0.1016 
Relative risk for progression rate from  compensated 
to decompensated cirrhosis (𝜌5) following SVR 




Relative risk for progression rate from compensated 
cirrhosis to HCC (𝜌6) following SVR 






What was included? 
Staff time, buildings use, capital equipment, training costs, supplies, consultancy. 
How was it measured? 
 Staff type and time was determined by questioning a subset of the staff involved.  Nurse 
facilitators were interviewed as well as the keyworkers involved in the buddy system 
operation in both Lincoln and Liverpool.   
 Buildings use was determined using fire safety floorplans of the buildings and questioning 
staff on room use to obtain an allocation percentage of the rent (and maintenance) per year.   
 Capital equipment was only laptops.   
 For supplies the cost of the testing kits and surgical gloves was included.   
 Training costs included staff time for training as well as the cost of providing the training 
itself where known.  In one of the settings, the nurse facilitator underwent lots of training at 
the start of the intervention but only the staff time was included in the costing as we did not 
have costs of the courses attended. 
 Consultancy was Hepatitis C Trust training that was given.  Expenses from the Hepatitis C 
Trust were included as well as their usual course fee (which was not paid in this instance) to 
obtain a full economic cost rather than the financial cost. 
 Expenses for meetings and training events were recorded although only those incurred for 
non-research purposes were included in the unit costs of the intervention   
Where are the reference costs from? 
Staff salaries for keyworkers were obtained from Addaction (mid value of the range given was used).  
Nurse facilitator salaries were obtained from the HepCATT study budgets.  NHS consultant salaries 
for hepatologists were taken from the NHS website.   Volunteers (both peers and buddies) were 
assumed to have an opportunity cost of the lowest paid key worker (one of the peers became a peer 
worker after the study).  Dried blood spot test costs (undertaken by Alere), were obtained from 
HepCATT study records.  Buildings and maintenance costs were obtained from Addaction (including 
rent, utilities, and cleaning). 
What assumptions were made? 
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Costs were separated out into fixed costs, which don’t depend on the number of tests or patients 
seen, and variable costs.  A fixed yearly cost was calculated for running the intervention using the 
management and training costs. Management costs included line management of staff, meetings for 
ongoing management of the intervention and training costs included staff training specific to the 
intervention.  It was assumed that in the first year (start up) of the intervention all of the costs would 
apply and in subsequent years there would be one training session by the Hep C Trust, costing £2500 
on average.   
For diagnosis costs, personnel time per test was calculated using the outcome data for each site, 
then the cost per test depended on whether the person tested was uninfected (antibody negative), 
in which case there was only the cost of the Ab test and a pair of gloves.  Otherwise, the laboratory 
cost of the RNA test was added.  For individuals who have been previously treated, only the RNA test 
cost was assumed in addition to personnel time. 
The cost of engagement was calculated using the number of referrals and number of engagements 
at each site.  Nurse facilitators were interviewed to determine proportion of their time spent on 
research related, managerial or admin, training, diagnosis or engagement tasks. The total cost of 
engagement included buddy and peer volunteer time as well as expenses. The nurse and key worker 
staff time was divided by the number of referrals plus volunteer time divided by the number of 
engaged.  To calculate engagement costs for those who were known positives the staff time cost for 
testing interview was used, as well as the engagement cost, to include the initial consultation time 




Table S9: Detailed costing inputs for the model – all costs in the table were inflated to 2018 prices 
after the analysis 
Step Standard of care Cost  Intervention Cost Source 
HepCATT startup cost for 
first year 
0 £24,854-£33,962 HepCATT costing analysis  
Second and Subsequent 
Years fixed costs for 
HepCATT 
0 £10,715-£13,519 
Costs per Test 
(includes staff 
time and test 
costs) 
Ab negative  £45 (staff cost)+ £7.4 
(Ab test cost) +/- 10% 
£104-£158 (11) and HepCATT costing 
analysis (see supplementary 
information) 
Ab positive  £45+£7.4+£64.2 (RNA 
test cost) +/- 10% 

















£325.84 +/- 10% (at 
hospital)+£75 (referral 
cost) 
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expert opinion 
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Figure S1: Model projections of treatments undertaken in PWID (a) and ex-injectors (b) since 2016 
with and without the HepCATT intervention. This is for the projections assuming 1000 PWID. The 
black solid or dashed lines show the median of the model projections with the shaded areas 
denoting the 95% central range of the model projections. 
(a) Current PWID 
 










Figure S2 Yearly discounted costs of the intervention and standard-of-care as well as the incremental 
cost each year. 
 
Figure S3 Cost-Effectiveness Plane for HepCATT intervention assuming full list price for HCV 




































Figure S5 ANCOVA Results: Contribution of uncertainty in each parameter to the variability in the 
results.  Parameters accounting for more than 3% of the uncertainty are shown individually. 
 
 
 
 
